Rybrevant (amivantamab) - originally developed by Danish biotech Genmab – has been cleared for NSCLC patients with exon 20 insertions, the third most common EGFR mutation in this form of lung ...

"As patients living with EGFR exon 20 insertion-mutated NSCLC face a particularly poor prognosis, the need for innovative combinations in the frontline setting is vital." EGFR mutations are the ...

for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The combination is also approved for a similar indication in the EU.

It targets EGFR exon 20, HER2 exon 20, and EGFR atypical mutations. These are particular genetic alterations found in certain NSCLC patients. In its ongoing Phase 1b clinical trial, ORIC ...

Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged prop-2-ynamide derivatives acting as EGFR (Exon 20 insertion [Ex20Ins] mutant) inhibitors reported to be useful for the ...